Two large studies have found that the two-drug combination of Tivicay (dolutegravir) and Edurant (rilpivirine) works as well as standard three- or four-antiretroviral (ARV) regimens. At the beginning of the clinical trial, the participants were taking a standard ARV regimen and had an undetectable viral load. They either remained on their original regimen or switched to ViiV Healthcare’s integrase inhibitor Tivicay plus Janssen’s non-nucleoside reverse transcriptase inhibitor Edurant. First and foremost, the researchers looked at the rates of those with an undetectable viral load after 48 weeks of treatment. These rates were comparable between the two treatment groups. Given the apparent success of the trials, ViiV will likely apply for approval for the Tivicay and Edurant regimen as a single tablet in 2017.